GlassScriptPhysician profile
Susan C Smith
NPI 1114296134
$1,526.64
in general payments reported to CMS, 2019-2025
20 companies · $52.52 in 2025
The $52.52 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $317 · 2022: $338 · 2023: $801 · 2024: $18.07 · 2025: $52.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $871.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $241.57 | 2021-2023 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $241.00 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $192.64 | 2021-2023 | Strensiq |
| Janssen Pharmaceuticals, INC | $123.17 | 2021-2023 | Spravato |
| Novartis Pharmaceuticals Corporation | $97.25 | 2022-2023 | |
| Amgen INC. | $78.98 | 2023 | Prolia, Evenity, Repatha |
| Janssen Biotech, INC. | $70.59 | 2024-2025 | Tremfya |
| Bayer Healthcare Pharmaceuticals INC. | $68.55 | 2022-2023 | |
| Lilly USA, LLC | $68.35 | 2022-2023 | Mounjaro |
| Pfizer INC. | $61.00 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $53.23 | 2022 | |
| Exact Sciences Corporation | $40.70 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $36.85 | 2023 | Trelegy Ellipta, Boostrix, Shingrix |
| Antares Pharma, INC. | $34.35 | 2022-2023 | Xyosted, Nocdurna, Tlando |
| Astrazeneca Pharmaceuticals LP | $29.75 | 2022-2023 | Airsupra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23.42 | 2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $19.62 | 2022 | |
| Ibsa Pharma INC. | $15.70 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.48 | 2023 | Xifaxan |
| Mylan Specialty L.P. | $14.44 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.